Meta-hlorofenilpiperazin

Izvor: Wikipedia
meta-Hlorofenilpiperazin
(IUPAC) ime
1-(3-hlorofenil)piperazin
Klinički podaci
Identifikatori
CAS broj 6640-24-0
ATC kod nije dodeljen
PubChem[1][2] 1355
ChemSpider[3] 1314
ChEBI CHEBI:10588 YesY
ChEMBL[4] CHEMBL478 YesY
Hemijski podaci
Formula C10H13ClN2 
Mol. masa 196,676 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Metabolizam Hepatic
Poluvreme eliminacije 2-6 sata
Izlučivanje Renalno
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status
Način primene Oralno, nazalno, rektalno

meta-Hlorofenilpiperazin (mCPP) je psihoaktivni lek iz fenilpiperazinske klase. On je razvijen krajem 1970-tih i korišten je u naučnim istraživanjima, pre nego što je postao dezijnirana droga sredinom 2000-tih.[5][6] mCPP je detektovan u pilulama koje su reklamirane kao legalne alternative za nedopuštne stimulanse u Novom Zelandu i u pilulama koje su prodavane kao "ekstazi" u Evropi i Sjedinjenim Državama.[7][8]

Uprkos pokušaja da se uvede u upotrebu kao rekreaciona supstanca, mCPP se zapravo generalno smatra nepoželjnim jer proizvodi neprijatna iskustva.[7] Njemu nedostaju potkrepljujući efekti,[9] proizvodi depresivne i anksiogene efekte kod glodara i ljudi,[10][11] i može da indukuje panične napade kod osoba koje su im podložne.[12][13][14][15] On takođe pogoršava opsesivno-kompulzivne simptome kod ljudi sa tim poremećajem.[16][17][18]

Vidi još[uredi - уреди]

References[uredi - уреди]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. doi:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. doi:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. doi:10.1093/nar/gkr777. PMID 21948594.  edit
  5. Bossong MG, Van Dijk JP, Niesink RJ (December 2005). "Methylone and mCPP, two new drugs of abuse?". Addiction Biology 10 (4): 321–3. doi:10.1080/13556210500350794. PMID 16318952. 
  6. Lecompte Y, Evrard I, Arditti J (2006). "[Metachlorophenylpiperazine (mCPP): a new designer drug]". Thérapie (in French) 61 (6): 523–30. PMID 17348609. 
  7. 7.0 7.1 Bossong M, Brunt T, Van Dijk J et al. (March 2009). "mCPP: an undesired addition to the ecstasy market". Journal of Psychopharmacology (Oxford, England) 24 (9): 1395–401. doi:10.1177/0269881109102541. PMID 19304863. 
  8. Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ (December 2009). "Content of ecstasy in the Netherlands: 1993-2008". Addiction (Abingdon, England) 104 (12): 2057–66. doi:10.1111/j.1360-0443.2009.02707.x. PMID 19804461. 
  9. Tancer M, Johanson CE (October 2003). "Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP". Drug and Alcohol Dependence 72 (1): 33–44. doi:10.1016/S0376-8716(03)00172-8. PMID 14563541. 
  10. Rajkumar R, Pandey DK, Mahesh R, Radha R (April 2009). "1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay". European Journal of Pharmacology 608 (1-3): 32–41. doi:10.1016/j.ejphar.2009.02.041. PMID 19269287. 
  11. Kennett GA, Whitton P, Shah K, Curzon G (May 1989). "Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists". European Journal of Pharmacology 164 (3): 445–54. doi:10.1016/0014-2999(89)90252-5. PMID 2767117. 
  12. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (November 1991). "Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects". Biological Psychiatry 30 (10): 973–84. doi:10.1016/0006-3223(91)90119-7. PMID 1756202. 
  13. Charney DS, Woods SW, Goodman WK, Heninger GR (1987). "Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects". Psychopharmacology 92 (1): 14–24. PMID 3110824. 
  14. Van Veen JF, Van der Wee NJ, Fiselier J, Van Vliet IM, Westenberg HG (October 2007). "Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 17 (10): 637–42. doi:10.1016/j.euroneuro.2007.03.005. PMID 17481859. 
  15. van der Wee NJ, Fiselier J, van Megen HJ, Westenberg HG (October 2004). "Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 14 (5): 413–7. doi:10.1016/j.euroneuro.2004.01.001. PMID 15336303. 
  16. Hollander E, DeCaria CM, Nitescu A et al. (January 1992). "Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers". Archives of General Psychiatry 49 (1): 21–8. PMID 1728249. 
  17. Broocks A, Pigott TA, Hill JL et al. (June 1998). "Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results". Psychiatry Research 79 (1): 11–20. doi:10.1016/S0165-1781(98)00029-8. PMID 9676822. 
  18. Pigott TA, Zohar J, Hill JL et al. (March 1991). "Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder". Biological Psychiatry 29 (5): 418–26. doi:10.1016/0006-3223(91)90264-M. PMID 2018816. 

Spoljašnje veze[uredi - уреди]